Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
Status:
Recruiting
Trial end date:
2031-07-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, single arm, open-label, Phase 2 study in high risk smoldering myeloma
patients. The primary objective is to determine the efficacy of Elranatamab in patients with
previously untreated high-risk SMM. The key-secondary objective is to determine the safety of
Elranatamab in patients with previously untreated high-risk SMM.